Mezzion Pharma Co Ltd
KOSDAQ:140410
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mezzion Pharma Co Ltd
Accrued Liabilities
Mezzion Pharma Co Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mezzion Pharma Co Ltd
KOSDAQ:140410
|
Accrued Liabilities
₩23.7B
|
CAGR 3-Years
27%
|
CAGR 5-Years
34%
|
CAGR 10-Years
69%
|
|
|
Yuhan Corp
KRX:000100
|
Accrued Liabilities
₩33.6B
|
CAGR 3-Years
77%
|
CAGR 5-Years
58%
|
CAGR 10-Years
38%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Accrued Liabilities
₩94.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Accrued Liabilities
₩63.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
0%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Accrued Liabilities
₩25B
|
CAGR 3-Years
32%
|
CAGR 5-Years
31%
|
CAGR 10-Years
20%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Accrued Liabilities
₩964.9m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Mezzion Pharma Co Ltd
Glance View
Mezzion Pharma Co., Ltd. engages in the development, production, and licensing of pharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2012-01-20. The firm focuses on development and manufacture of remedies for erectile dysfunction and benign prostatic hyperplasia. In addition, the Company engages in the development of remedies for portal hypertension (PH), pulmonary arterial hypertension (PAH), overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and others. The firm has sighed licensing contract with overseas partners, including Warner in America, Valenta in Russia, Nycomed in Mexico and Dr.Falk in Europe. On April 22, 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.
See Also
What is Mezzion Pharma Co Ltd's Accrued Liabilities?
Accrued Liabilities
23.7B
KRW
Based on the financial report for Dec 31, 2025, Mezzion Pharma Co Ltd's Accrued Liabilities amounts to 23.7B KRW.
What is Mezzion Pharma Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
69%
Over the last year, the Accrued Liabilities growth was 25%. The average annual Accrued Liabilities growth rates for Mezzion Pharma Co Ltd have been 27% over the past three years , 34% over the past five years , and 69% over the past ten years .
